MedTrace Logo

The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients

NCT02315833 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-02-17

No results posted yet for this study

Summary

The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.

Conditions

Interventions

DRUG

Acetium

Capsule for oral administration contains L-cysteine 100mg

DRUG

Placebo

A placebo capsule matching Acetium for oral administration.

Sponsors & Collaborators

  • The Finnish Funding Agency for Technology and Innovation (TEKES)

    collaborator OTHER_GOV

  • Biohit Oyj

    lead INDUSTRY

Principal Investigators

  • Kari Syrjänen, MD, PhD · Biohit Oyj

  • Mikko Kallela, MD, PhD · Helsingin Päänsärkykeskus Oy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-17
Primary Completion
2019-07-02
Completion
2020-09-07

Countries

  • Estonia
  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315833 on ClinicalTrials.gov